Pacer Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-418,331
| Closed | -$46.6M | – | 3540 |
|
|
2025
Q1 | $46.6M | Buy |
418,331
+18,321
| +5% | +$1.95M | 0.11% | 172 |
|
|
2024
Q4 | $38.9M | Buy |
400,010
+15,008
| +4% | +$1.6M | 0.08% | 232 |
|
|
2024
Q3 | $44.3M | Buy |
385,002
+9,934
| +3% | +$1.13M | 0.09% | 225 |
|
|
2024
Q2 | $39.9M | Sell |
375,068
-18,268
| -5% | -$1.83M | 0.09% | 221 |
|
|
2024
Q1 | $38M | Buy |
393,336
+5,516
| +1% | +$566K | 0.09% | 232 |
|
|
2023
Q4 | $39.2M | Buy |
387,820
+368,778
| +1,937% | +$35.6M | 0.11% | 204 |
|
|
2023
Q3 | $1.94M | Sell |
19,042
-1,114
| -6% | -$113K | 0.01% | 615 |
|
|
2023
Q2 | $2.03M | Sell |
20,156
-313,159
| -94% | -$31.3M | 0.01% | 722 |
|
|
2023
Q1 | $30.7M | Buy |
333,315
+100,479
| +43% | +$8.78M | 0.13% | 164 |
|
|
2022
Q4 | $21.1M | Buy |
232,836
+50,296
| +28% | +$4.24M | 0.11% | 156 |
|
|
2022
Q3 | $13.9M | Buy |
182,540
+44,305
| +32% | +$3.67M | 0.1% | 163 |
|
|
2022
Q2 | $11.7M | Buy |
138,235
+77,785
| +129% | +$6.82M | 0.09% | 200 |
|
|
2022
Q1 | $5.3M | Buy |
60,450
+9,491
| +19% | +$822K | 0.04% | 414 |
|
|
2021
Q4 | $4.46M | Buy |
50,959
+710
| +1% | +$59K | 0.05% | 504 |
|
|
2021
Q3 | $4.11M | Sell |
50,249
-435
| -0.9% | -$39.1K | 0.05% | 483 |
|
|
2021
Q2 | $4.62M | Buy |
50,684
+5,434
| +12% | +$484K | 0.07% | 377 |
|
|
2021
Q1 | $3.87M | Sell |
45,250
-2,217
| -5% | -$199K | 0.07% | 308 |
|
|
2020
Q4 | $4.48M | Buy |
47,467
+22,799
| +92% | +$1.99M | 0.08% | 199 |
|
|
2020
Q3 | $2.15M | Buy |
+24,668
| New | +$2.14M | 0.05% | 391 |
|
|
2020
Q1 | – | Sell |
-19,498
| Closed | -$1.85M | – | 968 |
|
|
2019
Q4 | $1.85M | Buy |
19,498
+5,737
| +42% | +$515K | 0.08% | 294 |
|
|
2019
Q3 | $1.2M | Buy |
13,761
+4,812
| +54% | +$432K | 0.03% | 748 |
|
|
2019
Q2 | $817K | Buy |
+8,949
| New | +$757K | 0.02% | 876 |
|
|
2018
Q4 | – | Sell |
-57,429
| Closed | -$4.43M | – | 887 |
|
|
2018
Q3 | $4.43M | Buy |
57,429
+4,765
| +9% | +$352K | 0.17% | 102 |
|
|
2018
Q2 | $3.56M | Buy |
52,664
+8,230
| +19% | +$568K | 0.16% | 108 |
|
|
2018
Q1 | $3.22M | Buy |
44,434
+12,640
| +40% | +$962K | 0.18% | 95 |
|
|
2017
Q4 | $2.39M | Buy |
31,794
+5,555
| +21% | +$419K | 0.17% | 110 |
|
|
2017
Q3 | $2.02M | Buy |
26,239
+1,654
| +7% | +$125K | 0.18% | 83 |
|
|
2017
Q2 | $1.84M | Buy |
+24,585
| New | +$1.74M | 0.18% | 78 |
|
|
2013
Q4 | $1.25M | Buy |
+15,099
| New | +$1.05M | 0.3% | 84 |
|
Other funds holding NVS
Pacer Advisors's NVS Position: Q2 2025 in Review
Pacer Advisors sold out of Novartis (NVS) in Q2 2025, closing a stake of 418,331 shares — an estimated $46.6M sold.
Pacer Advisors first reported a position in NVS in Q4 2013 and held it in 29 quarters. The position peaked at $46.6M in Q1 2025. 1,383 funds tracked by Wall St. Rank hold NVS as of Q2 2025.
- Pacer Advisors reported no remaining Novartis position as of Q2 2025 after selling out during the quarter.
- Pacer Advisors sold 418,331 Novartis shares in Q2 2025, an estimated $46.6M.
- Pacer Advisors first reported a position in Novartis in Q4 2013 and held it in 29 quarters.
- Pacer Advisors's Novartis position peaked at $46.6M in Q1 2025.
- 1,383 funds tracked by Wall St. Rank held Novartis as of Q2 2025.
Based on Pacer Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.